Outsourcing facilities should confirm whether any GLP-1 compounding relies on bulk substances, reassess whether any product is identical or nearly identical to an approved drug and document the basis for continuing any formulation in light of FDA's express statement that semaglutide and tirzepatide are not on the 503B bulks list or drug shortage list
Dean Jones PhD, Professor of biochemistry, Director of Nutritional Health Sciences, Emory University Randomised controlled trial of oral glutathione supplementation on body stores of glutathione
-OtherGenestra Products
Experience with teduglutide treatment for short bowel syndrome in clinical practice
Prema S, Tamboli FA, Bhyan B, Chellammal HSJ
This included 3,048 patients who were treated with GLP-1RAs and 3,048 who received other anti-diabetic or anti-obesity medications